DiaMedica Therapeutics Inc. Common Stock

DMAC CA25253X2077

💰
Capitalization
Small-cap

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

🔗
Website
https://www.diamedica.com
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
2
🙍
Insiders
2
Person Price Shares Total Published Completed
Jacinto Richard Ii
 3.50
USD 		400,000
Bought 		1,400,000
USD 		23/07/2025 23/07/2025
Wambeke David J.
CBO 		2.46
USD 		20,000
Bought 		49,200
USD 		16/11/2023 16/11/2023
Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include DiaMedica Therapeutics Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Last 52W Low 52W High All-Time Low All-Time High β
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Jacinto Richard Ii 1 1,400,000.00 1,400,000.00 23/07/2025 23/07/2025
Wambeke David J. 1 49,200.00 49,200.00 16/11/2023 16/11/2023

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.